Recombinant urate oxidase or uricase (rasburicase) is available for intravenous administration to control the very high serum levels of uric acid that are initially produced when chemotherapy drugs are started in certain types of highly proliferative cancers; usually aggressive non-Hodgkins lymphomas and leukemias that would otherwise cause "tumor lysis syndrome".